Pharmacological therapy of nonalcoholic steatohepatitis

Hepatology Research

Volumn 41, Issue 3, 2011, Pages 209-216

  Hojo, Mariko ^a   Watanabe, Sumio ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Liver fibrosis; Metabolic syndrome; Peroxisome proliferator activated receptor agonists

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; ATORVASTATIN; BETAINE; CANNABINOID; CIGLITAZONE; CLOFIBRATE; EXENDIN 4; EZETIMIBE; GLUCAGON LIKE PEPTIDE 1; LOSARTAN; METFORMIN; NATEGLINIDE; PENTOXIFYLLINE; PIOGLITAZONE; PRAVASTATIN; PROBUCOL; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; SIMVASTATIN; STATIN; TELMISARTAN; TETRAHYDROLIPSTATIN; TROGLITAZONE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VALSARTAN;

BODY MASS; CARDIOVASCULAR DISEASE; DIET; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; HEPATITIS; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 79951782880     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00780.x     Document Type: Review

References (67)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-8.
2. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-57.
3. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.
4. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-10.
5. Abdelmalek M, Ludwig J, Lindor KD. Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol 1995; 20: 127-30.
6. Promrat K, Kleiner DE, Niemeier HM etal. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121-9.
7. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-5.
8. Camera A, Hopps E, Caimi G. Metabolic syndrome: from insulin resistance to adipose tissue dysfunction. Minerva Med 2008; 99: 307-21.
9. Hotta K, Funahashi T, Arita Y etal. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-9.
10. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271: 665-8.
11. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-S112.
12. Watanabe S, Yaginuma R, Ikejim K, Miyzaki A. Liver diseases and metabolic syndrome. J Gastroenterol 2008; 43: 509-18.
13. McNear S, Harrison SA. Current status of therapy in nonalcoholic fatty liver disease. Ther Adv Gastroenterol 2009; 2: 29-43.
14. Agrawal S, Bonkovsky HL. Management of nonalcoholic steatohepatitis: an analytic review. J Clin Gastroenterol 2002; 35: 253-61.
15. Chang CY, Argo CK, Al-Osaimi AM, Caldwell SH. Therapy of NAFLD: antioxidants and cytoprotective agents. J Clin Gastroenterol 2006; 40 (Suppl 1): S51-60.
16. Stein LL, Dong MH, Loomba R. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: current status. Adv Ther 2009; 26: 893-907.
17. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009; 49: 306-17.
18. Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci 2010; 55: 560-78.
19. Zelber-Sagi S, Kessler A, Brazowsky E etal. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4: 639-44.
20. Hussein O, Grosovski M, Schlesinger S, Szvalb S, Assy N. Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH). Dig Dis Sci 2007; 52: 2512-9.
21. Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004; 20: 623-8.
22. Harrison SA, Fecht W, Brunt EM, Torgerson S, Hayashi P. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 2009; 49: 80-6.
23. Aithal GP, Thomas JA, Kaye PV etal. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008; 135: 1176-84.
24. Belfort R, Harrison SA, Brown K etal. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-307.
25. Promrat K, Lutchman G, Uwaifo GI etal. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39: 188-96.
26. Sanyal AJ, Chalasani N, Kowdley KV etal. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-85.
27. Sanyal AJ, Mofrad PS, Contos MJ etal. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004; 2: 1107-15.
28. Ratziu V, Giral P, Jacqueminet S etal. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135: 100-10.
29. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38: 1008-17.
30. Idilman R, Mizrak D, Corapcioglu D etal. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008; 28: 200-8.
31. Uygun A, Kadayifci A, Isik AT etal. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004; 19: 537-44.
32. Loomba R, Lutchman G, Kleiner DE etal. Clinical trial: Pilot study of metformin for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2008; 29: 172-82.
33. Bugianesi E, Gentilcore E, Manini R etal. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005; 100: 1082-90.
34. Nair S, Diehl AM, Wiseman M, Farr GH Jr, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004; 20: 23-8.
35. Omer Z, Cetinkalp S, Akyildiz M etal. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2010; 22: 18-23.
36. de Oliveira CP, Stefano JT, de Siqueira ER etal. Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. Hepatol Res 2008; 38: 159-65.
37. Morita Y, Ueno T, Sasaki N etal. Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes. Hepatogastroenterology 2005; 52: 1338-43.
38. Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol 2009; 15: 942-54.
39. Yokohama S, Yoneda M, Haneda M etal. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40: 1222-5.
40. Yokohama S, Tokusashi Y, Nakamura K etal. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol 2006; 12: 322-6.
41. Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004; 174: 193-6.
42. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol 2009; 43: 990-4.
43. Hyogo H, Tazuma S, Arihiro K etal. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008; 57: 1711-8.
44. Kimura Y, Hyogo H, Yamagishi S etal. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol 2010; 45: 750-7.
45. Park H, Shima T, Yamaguchi K etal. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 101-7.
46. Yoneda M, Fujita K, Nozaki Y etal. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open -label, pilot study. Hepatol Res 2010; 40: 566-73.
47. Merat S, Aduli M, Kazemi R etal. Liver histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol. Dig Dis Sci 2008; 53: 2246-50.
48. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003; 98: 2485-90.
49. Dufour JF, Oneta CM, Gonvers JJ etal. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006; 4: 1537-43.
50. Lindor KD, Kowdley KV, Heathcote EJ etal. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39: 770-8.
51. Leuschner UF, Lindenthal B, Herrmann G etal. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010; 52: 472-9.
52. Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis 2007; 16: 39-46.
53. Laurin J, Lindor KD, Crippin JS etal. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23: 1464-7.
54. Abdelmalek MF, Sanderson SO, Angulo P etal. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 2009; 50: 1818-26.
55. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001; 96: 2711-7.
56. Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007; 22: 634-8.
57. Ismail MH, Pinzani M. Reversal of liver fibrosis. Saudi J Gastroenterol 2009; 15: 72-9.
58. Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, Okita K. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun 2004; 315: 187-95.
59. Kon K, Ikejima K, Hirose M etal. Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun 2002; 291: 55-61.
60. Galli A, Crabb DW, Ceni E etal. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002; 122: 1924-40.
61. Lutchman G, Modi A, Kleiner DE etal. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007; 46: 424-9.
62. Argo CK, Iezzoni JC, Al-Osaimi AM, Caldwell SH. Thiazolidinediones for the treatment in NASH: sustained benefit after drug discontinuation? J Clin Gastroenterol 2009; 43: 565-8.
63. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71.
64. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298: 1189-95.
65. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37-46.
66. Ratziu V, Charlotte F, Heurtier A etal. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-906.
67. Lesmana CR, Hasan I, Budihusodo U etal. Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non-alcoholic steatohepatitis. J Dig Dis 2009; 10: 201-6.